Biofrontera Inc. (BFRI) Research

Biofrontera Inc. is a biopharmaceutical enterprise dedicated to the marketing and distribution of pharmaceutical products within the United States, specifically targeting various dermatological conditions. The company's portfolio includes Ameluz, a prescribed medication designed for photodynamic therapy. This treatment, utilized in conjunction with its licensor's RhodoLED lamp series, addresses mild-to-moderate actinic keratosis on the face and scalp through both localized (lesion-directed) and broader area (field-directed) applications. Furthermore, Biofrontera offers Xepi, a prescription cream indicated for the treatment of impetigo. The firm was founded in 2015 and operates from its headquarters located in Woburn, Massachusetts.

Market snapshot

Symbol
BFRI
Price
$0.99
Day change
+0.61%
Market cap
$12.6M
P/E ratio
-1.04x
52-week range
0.555-1.19
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Next earnings
in 2 months

Peer companies

  • Aytu BioPharma, Inc. (AYTU)
  • Cocrystal Pharma, Inc. (COCP)
  • Dogwood Therapeutics, Inc. (DWTX)
  • Evogene Ltd. (EVGN)
  • Gelteq Limited Ordinary Shares (GELS)
  • Imunon, Inc. (IMNN)
  • ProPhase Labs, Inc. (PRPH)
  • Sunshine Biopharma, Inc. (SBFM)

Recent insider activity

  • Weber Kevin Daniel — A-Award (20000 shares) on 2026-03-04
  • Luebbert Hermann — M-Exempt (137500 shares) on 2026-03-05
  • Luebbert Hermann — A-Award (125000 shares) on 2026-03-04
  • Luebbert Hermann — A-Award (125000 shares) on 2026-03-04
  • Luebbert Hermann — M-Exempt (137500 shares) on 2026-03-05

Open Biofrontera Inc. (BFRI) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.